- In June 2023, Ipsen announced that the U.S. FDA approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome. This marked a significant advancement, providing an additional treatment option for the debilitating itch associated with this rare genetic disorder
- In September 2022, Dupilumab (Dupixent) received approval for the treatment of Prurigo Nodularis in the U.S. (September 2022) and Canada (July 2023). This marked the first approved targeted therapy for Prurigo Nodularis, a chronic inflammatory skin condition characterized by intensely itchy nodules, signifying a paradigm shift in its treatment
- In March 2023, The European Commission approved Dupixent (dupilumab) for the treatment of severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy. This expanded indication makes Dupixent the first and only targeted medicine approved for this young age group in Europe and the U.S., addressing a significant unmet need
